Larimar Therapeutics (LRMR) Enterprise Value (2013 - 2025)
Larimar Therapeutics (LRMR) posted Enterprise Value of -$136.9 million for Q4 2025, up 21.99% on a QoQ basis from -$175.4 million in Q3 2025, and up 25.4% year-over-year from -$109.1 million in Q4 2024.
Larimar Therapeutics (LRMR) Enterprise Value (2013 - 2025) Analysis & Trends
Larimar Therapeutics' Enterprise Value history runs 13 years deep, the most recent figure standing at -$136.9 million for Q4 2025.
- Quarterly Enterprise Value rose 25.4% year-over-year to -$136.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$136.9 million (up 25.4% YoY) and the FY2025 annual result came in at -$136.9 million, up 25.4% from the prior year.
- Enterprise Value was -$136.9 million for Q4 2025 at Larimar Therapeutics, up from -$175.4 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$54.9 million in Q2 2022 and bottomed at -$227.3 million in Q1 2024.
- A 5-year average of -$125.7 million and a median of -$115.0 million in 2022 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value plunged 116.95% — and 2025, when it soared 38.72%.
- Larimar Therapeutics' Enterprise Value stood at -$70.1 million in 2021, then tumbled by 68.95% to -$118.4 million in 2022, then grew by 26.71% to -$86.8 million in 2023, then tumbled by 111.38% to -$183.5 million in 2024, then advanced by 25.4% to -$136.9 million in 2025.
- Business Quant data shows LRMR's Enterprise Value at -$136.9 million in Q4 2025, -$175.4 million in Q3 2025, and -$138.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | -61.40 Mn |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | -2.83 Mn |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | -4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Larimar Therapeutics | 37.05 Mn | -99.80 Mn | - | -136.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -136.85 Mn |
| Sep 30, 2025 | -175.44 Mn |
| Jun 30, 2025 | -138.52 Mn |
| Mar 31, 2025 | -157.53 Mn |
| Dec 31, 2024 | -183.45 Mn |
| Sep 30, 2024 | -203.71 Mn |
| Jun 30, 2024 | -226.06 Mn |
| Mar 31, 2024 | -227.30 Mn |
| Dec 31, 2023 | -86.79 Mn |
| Sep 30, 2023 | -95.59 Mn |
| Jun 30, 2023 | -104.20 Mn |
| Mar 31, 2023 | -111.50 Mn |
| Dec 31, 2022 | -118.43 Mn |
| Sep 30, 2022 | -124.70 Mn |
| Jun 30, 2022 | -54.92 Mn |
| Mar 31, 2022 | -62.60 Mn |
| Dec 31, 2021 | -70.10 Mn |
| Sep 30, 2021 | -84.50 Mn |
| Jun 30, 2021 | -70.60 Mn |
| Mar 31, 2021 | -81.44 Mn |